Participant demographics
| Demographics | |
|---|---|
| Consented (n = 12) | |
| Age (median) (range) (yr) | 14 (8–17) |
| Males (No.) (%) | 10 (83) |
| Treatment (No. of patients) | |
| Completed protocol therapy | 6 |
| Eligible, withdrawna | 6 |
| Completed 13C injection (n = 6) | |
| Age (median) (range) (yr) | 14 (10–17) |
| Males (No.) (%) | 5 (83) |
| Diagnosis (anatomic location) (No.) (%) | |
| Diffuse intrinsic pontine glioma (pons) | 3 (50) |
| Craniopharyngioma (suprasellar) | 1 (17) |
| Medulloblastoma (posterior fossa) | 1 (17) |
| Pineoblastoma (pineal gland) | 1 (17) |
| Dose level (No. of patients) | |
| Dose level 1 | 3 |
| Dose level 2 | 3 |
| Safety (No. of events) | |
| Dose level toxicity | 0 |
| Adverse events | 0 |
a Withdrawn due to the following: technical issue with MR imaging scanner (n = 1) or generating HP [1-13C]pyruvate (n = 3); change in participant choice to participate (n = 1); or disease progression before participation and participant did not return to University of California, San Francisco for follow-up treatment (n = 1).